methyl (4-mercapto-2-methyl-phenoxy)-acetate | 56077-47-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl (4-mercapto-2-methyl-phenoxy)-acetate
• 英文别名: (4-mercapto-2-methyl-phenoxy)-acetic acid methyl ester；Methyl (2-methyl-4-sulfanylphenoxy)acetate；methyl 2-(2-methyl-4-sulfanylphenoxy)acetate
• CAS: 56077-47-5
• 化学式: C₁₀H₁₂O₃S
• 分子量: 212.269
• InChiKey: QDEFPBCRTWICJS-UHFFFAOYSA-N

物化性质

• 沸点：
  316.8±27.0 °C(Predicted)
• 密度：
  1.187±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  36.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl (4-mercapto-2-methyl-phenoxy)-acetate 在 sodium hydroxide 、 三丁基膦 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 30.0h， 生成 {4-[3,3-Bis-(4-bromo-phenyl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid
  参考文献：
  名称：

  Identification and Synthesis of a Novel Selective Partial PPARδ Agonist with Full Efficacy on Lipid Metabolism In Vitro and In Vivo

  摘要：

  The aim was to identify a novel selective PPAR delta agonist with full efficacy on free fatty acid (FFA) oxidation in vitro and plasma lipid correction in vivo. Using the triple PPAR alpha,gamma,delta agonist 1 as the structural starting point, we wanted to investigate the possibility of obtaining selective PPAR delta agonists by modifying only the acidic part of 1, while holding the lipophilic half of the molecule constant. The structure-activity relationship was guided by in vitro transactivation data using the human PPAR receptors, FFA oxidation efficacy performed in the rat muscle L6 cell line, and in vivo rat pharmacokinetic properties. Compound 7 ([4-[3,3-bis-(4-bromo-phenyl)-allylthio]-2-chloro-phenoxy]-acetic acid) was identified as a selective, partial agonist with good oral pharmacokinetic properties in rat. Chronic treatment of high fat fed ApoB100/CETP-Tgn mice with 7 corrected the plasma lipid parameters and improved insulin sensitivity. These data suggest that selective PPAR delta agonists have the potential to become a novel treatment of dyslipidemia.

  DOI：

  10.1021/jm061202u
• 作为产物：
  描述：

  4-羟基-3-甲基苯乙酮 在 甲醇 、 4-二甲氨基吡啶 、 sodium methylate 、 caesium carbonate 、 对甲苯磺酸 、 三乙胺 、 间氯过氧苯甲酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 乙腈 为溶剂， 反应 54.0h， 生成 methyl (4-mercapto-2-methyl-phenoxy)-acetate
  参考文献：
  名称：

  Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activity

  摘要：

  We report the synthesis and biological activity of a new series of small molecule agonists of the human Peroxisome Proliferator-Activated Receptor delta (PPARdelta). Several hits were identified from our original libraries containing lipophilic carboxylic acids. Optimization of these hits by structure-guided design led to 7k (GW501516) and 71 (GW0742), which shows an EC50 Of 1.1 nM against PPARdelta with 1000-fold selectivity over the other human subtypes. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00207-5

文献信息

• [EN] DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS<br/>[FR] DERIVES D'ACIDE DICARBOXYLIQUE EN TANT QU'AGONISTES PPAR
  申请人：NOVO NORDISK AS

  公开号：WO2004056740A1

  公开（公告）日：2004-07-08

  A novel class of dicarboxylic acid derivatives, the use of these compounds as phar-maceutical compositions, pharmaceutical compositions comprising the compounds and meth-ods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Prolifera-tor-Activated Receptors (PPAR).

  一种新型的二元酸衍生物，这些化合物的用途作为药物组合物，包含这些化合物的药物组合物以及使用这些化合物和组合物进行治疗的方法。本发明的化合物可能用于治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的条件。
• Novel compounds, their preparation and use
  申请人：Jeppesen Lone

  公开号：US20050080115A1

  公开（公告）日：2005-04-14

  Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ suptype.

  通用公式（I）的新化合物，这些化合物作为药物组成部分的用途，包含这些化合物的药物组成部分以及使用这些化合物和组成部分进行治疗的方法。这些化合物可能在治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中有用，特别是PPARδ亚型。
• Compounds that modulate PPAR activity and methods of preparation
  申请人：——

  公开号：US20040209936A1

  公开（公告）日：2004-10-21

  This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.

  这项发明涉及改变PPAR活性的化合物。该发明还涉及这些化合物的药用盐、包含这些化合物或其盐的药用组合物，以及将它们用作治疗或预防哺乳动物中的脂质代谢异常、高胆固醇血症、肥胖、高血糖、动脉粥样硬化、高甘油三酯血症和高胰岛素血症的治疗剂的方法。本发明还涉及制备所述化合物的方法。
• Base Catalysis Enables Access to α,α-Difluoroalkylthioethers
  作者：Douglas L. Orsi、Brandon J. Easley、Ashley M. Lick、Ryan A. Altman

  DOI：10.1021/acs.orglett.7b00386

  日期：2017.4.7

  A nucleophilic addition reaction of aryl thiols to readily available β,β-difluorostyrenes provides α,α-difluoroalkylthioethers. The reaction proceeds through an unstable anionic intermediate, prone to eliminate fluoride and generate α-fluorovinylthioethers. However, the use of base catalysis overcomes the facile β-fluoride elimination, generating α,α-difluoroalkylthioethers in excellent yields and

  芳基硫醇与容易获得的β，β-二氟苯乙烯的亲核加成反应提供α，α-二氟烷基硫醚。反应通过不稳定的阴离子中间体进行，易于消除氟化物并生成α-氟乙烯基硫醚。然而，碱催化的使用克服了容易的β-氟化物消除，以优异的产率和选择性产生α，α-二氟烷基硫醚。
• Novel Bisaryl Substituted Thiazoles and Oxazoles as Highly Potent and Selective Peroxisome Proliferator-Activated Receptor δ Agonists
  作者：Robert Epple、Christopher Cow、Yongping Xie、Mihai Azimioara、Ross Russo、Xing Wang、John Wityak、Donald S. Karanewsky、Tove Tuntland、Vân T. B. Nguyêñ-Trân、Cara Cuc Ngo、David Huang、Enrique Saez、Tracy Spalding、Andrea Gerken、Maya Iskandar、H. Martin Seidel、Shin-Shay Tian

  DOI：10.1021/jm9007399

  日期：2010.1.14

  The discovery, synthesis, and optimization of compound 1 from a high-throughput screening hit to highly potent and selective peroxisome proliferator-activated receptor δ (PPARδ) agonists are reported. The synthesis and structure−activity relationship in this series are described in detail. On the basis of a general schematic PPAR pharmacophore model, scaffold 1 was divided into headgroup, linker, and

  从高通量筛选到高效和选择性的过氧化物酶体增殖物激活受体δ（PPARδ）激动剂的发现，合成和优化了化合物1。详细介绍了该系列中的合成和构效关系。基于通用的PPAR药效团模型示意图，支架1将其分为头基，接头和尾基，并使用体外PPAR反式激活分析对PPAR激活进行了优化。有效和选择性的PPARδ活化需要一个（2-甲基苯氧基）乙酸头基，一个柔性连接基和一个带有两个疏水性芳基取代基的五元杂芳族中心环。这些芳基取代基的微调导致了一系列高效且选择性的化合物（例如化合物38c）在小鼠体内表现出出色的药代动力学特性。在体内急性给药模型中，该阵列的选定成员显示出可诱导丙酮酸脱氢酶激酶4（PDK4）和解偶联蛋白3（UCP3）的表达，这些基因已知参与能量稳态并受其调节。骨骼肌中的PPARδ。